Market revenue in 2023 | USD 5.4 million |
Market revenue in 2030 | USD 12.4 million |
Growth rate | 12.5% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Illumina Inc, Qiagen NV, Abcam PLC, Takara Bio Inc, Revvity Inc, Maravai LifeSciences Holdings Inc Ordinary Shares - Class A, HTG Molecular Diagnostics Inc, Meridian Bioscience, New England Biolabs, Norgen Biotek, System Biosciences, Amoy Diagnostics, EntroGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mirna sequencing and assay market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 81.48% in 2023. Horizon Databook has segmented the Brazil mirna sequencing and assay market based on product, services covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil holds the largest share in the miRNA sequencing and assay market in the Latin American region. The country is expected to show significant growth owing to increasing number of research studies being undertaken in the country in the past few years along with significant investment in stem cell research, especially embryonic & induced pluripotent cells.
The prevalence of chronic diseases and the aging population are expected to increase demand for miRNA-guided diagnostics in the country, thereby contributing to growth of miRNA sequencing and assay market. The developing biotechnology sector in Brazil is a key driving force for this market.
Supportive government initiatives, such as the collaboration between the U.S. and Brazil on biomedical research to accelerate R&D, are also aiding market growth. In addition, the Brazilian Ministry of Health funded a study in which a team of scientists evaluated miRNAs as biomarkers for early cancer diagnosis. Hence, availability of government support and funding is likely to fuel overall market in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil mirna sequencing and assay market , including forecasts for subscribers. This country databook contains high-level insights into Brazil mirna sequencing and assay market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account